Wall Street brokerages expect BioTelemetry Inc (NASDAQ:BEAT) to post earnings per share (EPS) of $0.43 for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for BioTelemetry’s earnings. The lowest EPS estimate is $0.41 and the highest is $0.43. BioTelemetry posted earnings of $0.39 per share in the same quarter last year, which would suggest a positive year over year growth rate of 10.3%. The company is expected to report its next earnings report on Wednesday, April 24th.
On average, analysts expect that BioTelemetry will report full-year earnings of $1.94 per share for the current year, with EPS estimates ranging from $1.80 to $2.18. For the next financial year, analysts forecast that the business will report earnings of $2.19 per share, with EPS estimates ranging from $2.09 to $2.36. Zacks’ earnings per share averages are a mean average based on a survey of analysts that cover BioTelemetry.
BioTelemetry (NASDAQ:BEAT) last released its quarterly earnings data on Thursday, February 21st. The medical research company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.13. The business had revenue of $103.60 million for the quarter, compared to analyst estimates of $102.84 million. BioTelemetry had a return on equity of 24.46% and a net margin of 10.72%. BioTelemetry’s revenue was up 13.0% compared to the same quarter last year. During the same period last year, the firm posted $0.32 earnings per share.
NASDAQ:BEAT opened at $59.16 on Friday. The stock has a market capitalization of $2.05 billion, a P/E ratio of 30.49 and a beta of 1.43. The company has a current ratio of 2.96, a quick ratio of 2.81 and a debt-to-equity ratio of 0.62. BioTelemetry has a twelve month low of $32.65 and a twelve month high of $80.92.
In other news, VP Heather C. Getz sold 93,383 shares of BioTelemetry stock in a transaction dated Tuesday, January 29th. The stock was sold at an average price of $70.06, for a total transaction of $6,542,412.98. Following the sale, the vice president now directly owns 119,085 shares of the company’s stock, valued at $8,343,095.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Heather C. Getz sold 10,590 shares of BioTelemetry stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $70.41, for a total value of $745,641.90. Following the sale, the vice president now directly owns 80,661 shares in the company, valued at $5,679,341.01. The disclosure for this sale can be found here. Insiders have sold 177,198 shares of company stock worth $12,419,736 over the last three months. Insiders own 6.50% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its stake in shares of BioTelemetry by 2.7% in the fourth quarter. BlackRock Inc. now owns 5,092,773 shares of the medical research company’s stock worth $304,141,000 after acquiring an additional 134,956 shares during the period. Vanguard Group Inc. lifted its stake in shares of BioTelemetry by 2.8% in the third quarter. Vanguard Group Inc. now owns 1,900,117 shares of the medical research company’s stock worth $122,462,000 after acquiring an additional 52,363 shares during the period. Vanguard Group Inc lifted its stake in shares of BioTelemetry by 2.8% in the third quarter. Vanguard Group Inc now owns 1,900,117 shares of the medical research company’s stock worth $122,462,000 after acquiring an additional 52,363 shares during the period. Geode Capital Management LLC lifted its stake in shares of BioTelemetry by 11.8% in the fourth quarter. Geode Capital Management LLC now owns 376,618 shares of the medical research company’s stock worth $22,490,000 after acquiring an additional 39,722 shares during the period. Finally, Deutsche Bank AG lifted its stake in shares of BioTelemetry by 119.7% in the fourth quarter. Deutsche Bank AG now owns 310,751 shares of the medical research company’s stock worth $18,556,000 after acquiring an additional 169,306 shares during the period. 88.51% of the stock is currently owned by institutional investors.
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
Featured Article: What Does a Sell-Side Analyst Rating Mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.